Announcements Trials
Browse Landscape

Status

Unknown 7Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 7Observational 2

Sponsor

Cancer Type

Breast 2

Conditions

HER2-positive Breast Cancer 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 58Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Reverse Transcriptase Polymerase Chain Reaction 39Bevacizumab 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Therapeutics 24Neoadjuvant Therapy 24Hepatectomy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Observational × pyrotinib × Clear all
NCT05572645 2024-02-26

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Fudan University

Completed
333 enrolled
Breast

Breast Neoplasms

NCT04756921 2021-02-16

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Fudan University

Completed
30 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡